Experimental combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT04098081
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have already tried at least two other therapies. Researchers will measure how many patients' tumors shrink and how long the disease is controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- galeterone and gemcitabine
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced pancreatic cancer who have run out of standard options.
- What could go wrong
- This is a small, early-phase trial with only 15 participants, so results may not apply broadly. The drug combination may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can a targeted antibody slow advanced pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer